Lilly Says Its Alzheimer's Drug Significantly Slowed Cognitive And Functional Decline
18/7 09:05
(RTTNews) - Eli Lilly and Company's (LLY), investigational drug donanemab significantly slowed cognitive and functional decline in people with early symptomatic Alzheimer's disease (AD), according to data presented by the company on Monday at the 2023 Alzheimer's Association Int...